# US 2005/0037487 A1 · Recombinant influenza vectors with a PolII promoter and ribozymes for vaccines and gene therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0037487 A1
- Document ID: US20050037487A1
- Status: Published application
- Kind: A1
- Application number: 10/855,975
- Filed: 2004-05-27
- Published: 2005-02-17
- Earliest claimed: 2003-05-28
- Assignees: Wisconsin Alumni Research Foundation
- Inventors: Yoshihiro Kawaoka; Stefan Hamm; Hideki Ebihara
- Web page: https://patentgrep.com/patent/US20050037487A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- C12N 15/86: Viral vectors
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/525: {Virus}
- A61K 2039/5256: {expressing foreign proteins}
- C12N 2760/16143: viral genome or elements thereof as genetic vector
- C12N 2760/16145: Special targeting system for viral vectors
- C12N 2760/16151: Methods of production or purification of viral material
- C12N 2800/108: episomal vectors
- C12N 2800/30: Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- C12N 2810/6081: rhabdoviridae, e.g. VSV
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides a composition useful to prepare influenza viruses, e.g., in the absence of helper virus, using vectors which include Po1II promoters and multiple ribozyme sequences.

## Claims

### Claim 1

A composition comprising a plurality of orthomyxovirus vectors, comprising
a) at least two vectors selected from a vector comprising a promoter operably linked to an influenza virus PA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB1 cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB2 cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus HA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus NP cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus NA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus M cDNA linked to a transcription termination sequence, or a vector comprising a promoter operably linked to an influenza virus NS cDNA linked to a transcription termination sequence, wherein at least one vector comprises a RNA polymerase II promoter linked to a first ribozyme sequence linked to the viral cDNA linked to a second ribozyme sequence linked to the transcription termination sequence; and
b) at least two vectors selected from a vector comprising a promoter operably linked to a DNA segment encoding influenza virus PA, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus PB1, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus PB2, or a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NP.

### Claim 2 (depends on 1)

The composition of claim 1 wherein the vectors of b) further include a vector comprising a promoter operably linked to a DNA segment encoding influenza virus HA, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NA, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus M1, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus M2, or a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NS2.

### Claim 3

A composition comprising a plurality of orthomyxovirus vectors, comprising
a) at least two vectors selected from a vector comprising a promoter operably linked to an influenza virus PA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB1 cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB2 cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus HA cDNA linked to a transcription termination sequence, a vector comprising promoter operably linked to an influenza virus NP cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus cDNA for NB and NA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus M cDNA linked to a transcription termination sequence, or a vector comprising a promoter operably linked to an influenza virus NS cDNA linked to a transcription termination sequence, wherein at least one vector comprises a RNA polymerase II promoter linked to a first ribozyme sequence linked to the viral cDNA linked to a second ribozyme sequence linked to the transcription termination sequence; and
b) at least two vectors selected from a vector comprising a promoter operably linked to a DNA segment encoding influenza virus PA, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus PB1, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus PB2, or a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NP.

### Claim 4 (depends on 3)

The composition of claim 3 wherein the vectors of b) further include a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NP, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus HA, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NA and NB, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus M, or a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NS2.

### Claim 5 (depends on 1, 3)

The composition of claim 1 or 3 wherein the HA is a type A HA.

### Claim 6 (depends on 1, 3)

The composition of claim 1 or 3 wherein the HA is a type B HA.

### Claim 7 (depends on 1, 3)

The composition of claim 1 or 3 wherein a plurality of the vectors of a) comprise a RNA polymerase II promoter.

### Claim 8 (depends on 1, 3)

The composition of claim 1 or 3 wherein all of the vectors of a) comprise a RNA polymerase II promoter.

### Claim 9 (depends on 1, 3)

The composition of claim 1 or 3 wherein each vector of a) is on a separate plasmid.

### Claim 10 (depends on 1, 3)

The composition of claim 1 or 3 wherein each vector of b) is on a separate plasmid.

### Claim 11 (depends on 1, 3)

The composition of claim 1 or 3 wherein the promoter of one or more vectors but not all of the vectors of a) is a RNA polymerase I promoter, RNA polymerase III promoter, T7 promoter, or T3 promoter.

### Claim 12 (depends on 11)

The composition of claim 11 wherein the RNA polymerase I promoter is a human RNA polymerase I promoter.

### Claim 13 (depends on 1, 3)

The composition of claim 1 or 3 wherein the each of the vectors of b) further comprise a RNA transcription termination sequence.

### Claim 14 (depends on 11)

The composition of claim 11 wherein the transcription termination sequence of the one or more vectors that do not comprise the RNA polymerase II promoter, is a RNA polymerase I transcription termination sequence, a RNA polymerase III transcription termination sequence or a ribozyme.

### Claim 15 (depends on 1, 3)

The composition of claim 1 or 3 further comprising a vector comprising a promoter linked to 5′ orthomyxovirus sequences comprising 5′ orthomyxovirus noncoding sequences linked to a cDNA of interest linked to 3′ orthomyxovirus sequences comprising 3′ orthomyxovirus noncoding sequences linked to a transcription termination sequence.

### Claim 16 (depends on 15)

The composition of claim 15 wherein the cDNA of interest is in the sense orientation.

### Claim 17 (depends on 15)

The composition of claim 15 wherein the cDNA of interest is in the antisense orientation.

### Claim 18 (depends on 15)

The composition of claim 15 wherein the cDNA of interest comprises an open reading frame encodes an immunogenic polypeptide or peptide of a pathogen or a therapeutic polypeptide or peptide.

### Claim 19 (depends on 1, 3)

The composition of claim 1 or 3 further comprising a vector comprising a RNA polymerase II promoter linked to a first ribozyme sequence linked to 5′ orthomyxovirus sequences comprising 5′ orthomyxovirus noncoding sequences linked to the cDNA of interest linked to 3′ orthomyxovirus sequences comprising 3′ orthomyxovirus noncoding sequences linked to a second ribozyme sequence linked to a transcription termination sequence.

### Claim 20 (depends on 19)

The composition of claim 19 wherein the cDNA of interest comprises an open reading frame encodes an immunogenic polypeptide or peptide of a pathogen or a therapeutic polypeptide or peptide.

### Claim 21 (depends on 1, 3)

A method to prepare influenza virus, comprising: contacting a cell with the composition of claim 1 or 3 in an amount effective to yield infectious influenza virus.

### Claim 22 (depends on 21)

The method of claim 21 further comprising isolating the virus.

### Claim 23 (depends on 21)

Virus obtained by the method of claim 21.

### Claim 24 (depends on 15, 19)

A method to prepare a gene delivery vehicle, comprising: contacting cells with the composition of claim 15 or 19 in an amount effective to yield influenza virus, and isolating the virus.

### Claim 25 (depends on 24)

Virus obtained by the method of claim 24.

### Claim 26 (depends on 1, 3)

A cell contacted with the composition of claim 1 or 3.

### Claim 27 (depends on 23, 25)

A cell infected with the virus of claim 23 or 25.

### Claim 28

A vector comprising a RNA polymerase II promoter linked to a first ribozyme sequence linked to an influenza virus cDNA linked to a second ribozyme sequence, wherein the influenza virus cDNA is an influenza virus PA cDNA, an influenza virus PB1 cDNA, an influenza virus PB2 cDNA, an influenza virus NP cDNA, an influenza virus HA cDNA, an influenza virus NA cDNA, an influenza virus M1 cDNA, an influenza virus M2 cDNA, an influenza virus NS2 cDNA, an influenza virus BM2 cDNA, or an influenza virus NS cDNA.

### Claim 29 (depends on 28)

The vector of claim 28 further comprising a RNA polymerase II transcription termination sequence linked to the second ribozyme sequence.

### Claim 30

A method to prepare influenza virus, comprising contacting a cell with a vector comprising a promoter operably linked to an influenza virus PA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB1 cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB2 cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus HA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus NP cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus NA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus M cDNA linked to a transcription termination sequence, and a vector comprising a promoter operably linked to an influenza virus NS cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus PA, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus PB1, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus PB2, and a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NP, so as to yield infectious virus, wherein the promoter in at least one vector comprising a viral cDNA comprises a RNA polymerase II promoter linked to a first ribozyme sequence linked to the viral cDNA linked to a second ribozyme sequence linked to a transcription termination sequence.

### Claim 31 (depends on 30)

The method of claim 30 further comprising a vector comprising a promoter operably linked to a DNA segment encoding influenza virus HA, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NA, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus M1, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus M2, and a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NS2.

### Claim 32

A method to prepare influenza virus, comprising contacting a cell with a vector comprising a promoter operably linked to an influenza virus PA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB1 cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB2 cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus HA cDNA linked to a transcription termination sequence, a vector comprising promoter operably linked to an influenza virus NP cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus cDNA for NB and NA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus M cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus NS cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus PA, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus PB1, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus PB2, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NP, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus HA, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NA, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus M, and a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NS2, wherein at least one vector comprising a viral cDNA comprises a RNA polymerase II promoter linked to a first ribozyme sequence linked to the viral cDNA linked to a second ribozyme sequence linked to the transcription termination sequence.

### Claim 33 (depends on 32)

The method of claim 32 further comprising a vector comprising a promoter operably linked to a DNA segment encoding influenza virus HA, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NA and NB, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus M, a vector comprising a promoter operably linked to a DNA segment encoding influenza virus BM2, and a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NS2.

### Claim 34 (depends on 30, 32)

The method of claim 30 or 32 further comprising a vector comprising a promoter linked to 5′ influenza virus sequences comprising 5′ influenza virus noncoding sequences linked to a cDNA of interest or a fragment thereof linked to 3′ influenza virus sequences comprising 3′ influenza virus noncoding sequences linked to a transcription termination sequence.

### Claim 35 (depends on 30, 32)

The method of claim 30 or 32 further comprising a vector comprising a RNA polymerase II promoter linked to a first ribozyme sequence linked to linked to 5′ influenza virus sequences comprising 5′ influenza virus noncoding sequences linked to the cDNA of interest or a fragment thereof linked to 3′ influenza virus sequences comprising 3′ influenza virus noncoding sequences linked to a second ribozyme sequence linked to a transcription termination sequence.

### Claim 36 (depends on 34)

The method of claim 34 wherein the cDNA of interest comprises an open reading frame encodes an immunogenic polypeptide or peptide of a pathogen or a therapeutic polypeptide or peptide.

### Claim 37 (depends on 35)

The method of claim 35 wherein the cDNA of interest comprises an open reading frame encodes an immunogenic polypeptide or peptide of a pathogen or a therapeutic polypeptide or peptide.

### Claim 38 (depends on 30, 32)

The method of claim 30 or 32 wherein the HA is a type A HA.

### Claim 39 (depends on 30, 32)

The method of claim 30 or 32 wherein the HA is a type B HA.

### Claim 40 (depends on 30, 32)

The method of claim 30 or 32 wherein all the vectors of a) comprise a RNA polymerase II promoter.

### Claim 41 (depends on 30, 32)

The method of claim 30 or 32 further comprising isolating the virus.

### Claim 42 (depends on 30, 32)

Virus obtained by the method of claim 30 or 32.

### Claim 43 (depends on 42)

A cell contacted with the virus of claim 42.

### Claim 44 (depends on 42)

A cell infected with the virus of claim 42.

### Claim 45 (depends on 42)

A method to immunize an individual against a pathogen, comprising administering to the individual an amount of the virus of claim 42 effective to immunize the individual.
